GeneDx Holdings Corp.

For the period ended Dec 31, 2025. Filed Feb 23, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 23, 2026

WGS$54.83-16.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share and share amounts)

	Year ended December 31,
	2025	2024	2023
Revenue
Diagnostic test revenue	$416,668	$302,157	$195,654
Other revenue	10,871	3,293	6,912
Total revenue	427,539	305,450	202,566
Cost of services	129,366	111,053	112,560
Gross profit	298,173	194,397	90,006
Research and development	72,026	45,722	58,266
Selling and marketing	88,405	67,371	60,956
General and administrative	150,819	104,517	139,021
Impairment loss	—	—	10,402
Other operating expenses, net	—	—	1,957
Loss from operations	(13,077)	(23,213)	(180,596)
Non-operating (expenses) income, net
Change in fair value of financial liabilities	(1,204)	(13,370)	1,170
Interest (expense) income, net	(2,539)	(3,032)	1,114
Other (expense) income, net	(4,317)	(13,014)	1,619
Total non-operating (expense) income, net	(8,060)	(29,416)	3,903
Loss before income taxes	(21,137)	(52,629)	(176,693)
Income tax benefit	116	343	926
Net loss	$(21,021)	$(52,286)	$(175,767)
Other comprehensive income, net of tax
Unrealized gain related to available for sale securities, net	106	405	425
Comprehensive loss	$(20,915)	$(51,881)	$(175,342)
Basic and diluted weighted average shares outstanding of Class A common stock	28,641,734	26,891,213	24,311,989
Basic and diluted net loss per share, Class A common stock	$(0.73)	$(1.94)	$(7.23)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.